Immuneering Corporation (IMRX)
1.96
-0.05 (-2.49%)
At close: Jan 14, 2025, 3:59 PM
1.99
1.49%
Pre-market Jan 15, 2025, 08:52 AM EST
undefined% (undefined)
| Bid | 1.97 |
| Market Cap | 60.86M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | -0.99 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.99 |
| Volume | 788,813 |
| Avg. Volume (20D) | 2,415,745 |
| Open | 2.07 |
| Previous Close | 2.01 |
| Day's Range | 1.95 - 2.07 |
| 52-Week Range | 1.00 - 7.68 |
| Beta | undefined |
About IMRX
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 66
Stock Exchange NASDAQ
Ticker Symbol IMRX
Website https://immuneering.com
Analyst Forecast
According to 7 analyst ratings, the average rating for IMRX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 563.27% from the latest price.
Buy 57.14%
Hold 42.86%
Sell 0.00%
1 week ago ·
Source
+0%
Immuneering shares are trading higher after the co...
Unlock content with
Pro Subscription
3 weeks ago ·
Source
+13.58%
Immuneering shares are trading higher after the company announced it launched a pancreatic cancer advisory board.
